美国生物制药公司托尼克斯制药控股公司（Tonix Pharmaceuticals Holding Co，股票代码：TNXP）周五盘前大涨7.28%，引发市场广泛关注。这一显著涨幅出现在公司发布第二季度财报后，尽管财报显示业绩不及预期。
根据最新发布的财报，托尼克斯制药第二季度调整后每股亏损3.86美元，高于分析师预期的3.21美元亏损。公司营收为200万美元，同比下降9.5%，也低于分析师预期的243万美元。尽管季度业绩表现不佳，但投资者似乎对公司的长期前景保持乐观态度。
值得注意的是，尽管季度业绩欠佳，托尼克斯制药的股价表现依然强劲。据报道，该公司股价在过去一个季度上涨了71.1%，今年迄今为止已上涨86.7%。同时，华尔街分析师对公司保持积极态度，目前对该股的平均评级为"买入"。分析师给予托尼克斯制药12个月目标价中位数为65.00美元，较前一交易日收盘价高出约5.3%。这些因素可能是支撑股价持续上涨的重要原因，反映了投资者对公司长期发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.